To, da za zdravilo ni Big Pharmsa sponzorja, ki bi plačal za 100% RCT ne pomeni, da je protokol vprašljiv. Od kje to tebi?Lepo, da priznaš, da forsirajo vprašljive protokole.
FLCCC ima veliko število podpornikov, naredite crowd funding campain, ni vrag, da ne boste napraskali takega drobiža. Če je imel samo abstract umaknjenega članka 85.000 ogledov, podpornikov pa še nekajkrat več, problema sploh ni.
Je z njimi kaj narobe?Pa ne da si res še enkrat nalimal te grafe?
Super, važno da za dodatno zav. plačujemo 420/leto; 4200/10let; 16.800/40letTo grem jest lepo h Kralju samoplačniško.
Mislis, da so pri cepivih sli po vseh 'regelcih'?Zdravila za neko uporabo ne moreš registrirati, če ni izvedena primerna študija. Šef FLCCCja bi hvatal krivine in se zanašal na nekakšne miniaturne "uncontrolled" študije. Sorry, tako ne gre.
Med tem pa je Merck ze dobil 356 milijonov dolarjev davkoplacevalskega denarja za eksperimentalno zdravilo za Covid, zdaj pa se 1.2 milijarde dolarjev davkoplacevalskega denarja.In kdo bo financiral 'primerno študijo'?
Kdo bi, v času pandemije, moral financirati tako študijo za zdravilo, pri katerem ni (več) profita? Le kdo se financira iz davkoplačevalskega denarja?
Konflikt interesov? Kje pa.Absolutely nothing has been written about the fact that the study was sponsored by Centro de Estudios en Infectogía Pediatrica and the authors were paid by 3 drug companies making COVID vaccines–Sanofi Pasteur, GlaxoSmithKline, and Janssen– and two making COVID therapeutics–Gilead and Merck.
Not only was the JAMA article used by WHO to support their recommendation against ivermectin, but it is also the main reference for European Medicines Agency (EMA) and the french “Agence Nationale de Securité du Médicament” (ANSM) in support of their negative recommendations. In January 2021, ANSM was pressed by means of justice to examine a “RTU” (sort of an emergency approval) for ivermectin. https://blog-gerard.maudrux.fr/2021/01/27/livermectine-au-conseil-detat/
But ANSM took its time and answered “no” on april 1st, after the JAMA article was published, taking it as “the” evdience ivermectin in not efficient.
Rabiš klic in 1 teden čakanja. No pa ene 50-100€ v žepu.Veš da že čakam več kot leto, da pridem na pregled. Dve me konkrtetno srbita in mi ne dasta miru.
Na koncu bom v statistiki zaradi posledic nedelovanja ....
Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial
Conclusions There were significantly lower viral loads and viable cultures in the ivermectin group, which could lead to shortening isolation time in these patients.
In to spremeni rezultate kako?Spet lepiš preprinte.